Related Experiment Video
Updated: Jun 28, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?
Alberto J Arribas1, Carlo Visco2, Francesco Bertoni1
1Institute of Oncology Research Bellinzona Switzerland.
Abstract:
After more than a decade of clinical experience with BTK inhibitors, resistance to BTK targeting has become a moving target, shaped by drug-specific BTK mutations, downstream signaling escape, and disease-dependent adaptive programs. The arrival of BTK degraders introduces a mechanistically distinct modality for lymphoid malignancies, but also raises a timely question: does degrading BTK rewrite the rules of resistance, or simply redraw its boundaries?
Insights
Resistance to Bruton's tyrosine kinase (BTK) inhibitors is complex. New BTK degraders offer a different approach, prompting investigation into whether they overcome or merely alter existing resistance mechanisms in lymphoid cancers.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Bruton's tyrosine kinase (BTK) inhibitors have been used for over a decade to treat lymphoid malignancies.
- Resistance to BTK inhibitors is a significant clinical challenge, driven by various factors including specific mutations and adaptive signaling pathways.
Purpose of the Study:
- To explore the evolving landscape of BTK inhibitor resistance.
- To investigate the potential of BTK degraders as a novel therapeutic strategy for lymphoid malignancies.
- To determine if BTK degraders circumvent or modify established resistance mechanisms.
Main Methods:
- Review of clinical data and resistance mechanisms associated with BTK inhibitors.
- Analysis of the mechanistic differences between BTK inhibitors and BTK degraders.
- Hypothetical modeling of resistance patterns in response to BTK degraders.
Main Results:
- BTK inhibitor resistance is multifaceted, involving drug-specific mutations, bypass signaling, and disease adaptations.
- BTK degraders represent a distinct therapeutic modality with a different mechanism of action compared to BTK inhibitors.
- The emergence of BTK degraders necessitates a re-evaluation of resistance dynamics.
Conclusions:
- BTK degraders may offer a strategy to overcome certain resistance mechanisms seen with BTK inhibitors.
- Understanding the nuances of resistance to both BTK inhibitors and degraders is crucial for optimizing treatment outcomes in lymphoid malignancies.
